U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07793461) titled 'Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics' on Aug. 26.
Brief Summary: The main treatment for Parkinson's disease is a medication called levodopa. Levodopa has to be absorbed from the gut and travel to the brain to work, but a naturally occurring enzyme in the lining of the stomach, called dopamine decarboxylase (AADC), can break some of it down before it ever reaches the brain. We do not yet know whether people whose stomachs have more of this enzyme absorb less of their levodopa dose, have worsened gastrointestinal (GI) symptoms associated with levodopa intake, and whether that affects how well the medic...